Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Lactobacillus reuteri strain GMNL-263 capable of improving hypertension and composition thereof

A technology of GMNL-263 and Lactobacillus reuteri, applied in the field of microbiology, can solve the problems of few human clinical data, pollution, no test data support, etc.

Active Publication Date: 2019-10-29
GENMONT BIOTECH
View PDF3 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0013] China Taiwan Patent Publication No. TW 201305331 and Chinese Patent Publication No. CN 102098923A disclose Swiss lactic acid bacteria, which can metabolize through animal milk to produce fermentation products VPP (Valine-Proline-Proline, valine-proline-proline) and IPP (Isoleucine-Proline-Proline, isoleucine-proline-proline), can inhibit ACE, as a hypotensive agent; however, this invention is based on the inference that VPP and IPP have been reported to have the ability to inhibit ACE , and there is a conclusion that fermented milk can be used to lower blood pressure. However, there is no experimental data to support this invention, and this invention is still administered in the form of live bacteria. In terms of efficacy, risk of live bacteria preservation, and acceptable groups of fermented milk ingredients, it is still potential problem
[0014] China Taiwan Patent Publication No. TW 200603741 discloses a method for preparing functional fermented milk containing ACE inhibitors, the steps of which include inoculating an appropriate amount of lactic acid bacteria selected from the genus Lactobacillus into a raw material for fermented milk (Lactobacillus spp.), Streptococcus (Streptococcus spp.) and Bifidobacterium (Bifidobacterium spp.), the lactic acid bacteria produce ACE inhibitory peptides through fermented milk, and it has been confirmed by mouse animal experiments The effect of lowering blood pressure; however, because this invention is also administered by the live bacteria form of fermented milk, it still has the aforementioned potential risks of unknown efficacy and limited acceptable groups of live bacteria preservation and fermented milk components, and there are only small Rat experimental data, no human data to support the efficacy
[0015] Although there have been related inventions that propose probiotics as a method of lowering blood pressure, there are few human clinical data to support the method because it is a health food, and if the specified effect is to be achieved, the amount of bacteria needs to be quite required, and often needs to be combined ACE-inhibiting peptides are administered as live bacteria in the form of fermented milk; in addition, except for L. The research of .helveticus also requires fermented milk in the form of live bacteria combined with the mechanism of ACE inhibitory peptides to achieve the effect of lowering blood pressure. However, fermented milk has the risk of preservation of live bacteria and contamination, and the added ingredients are not suitable for ingestion of excess sugar. Or for those who need to control the heat, it is still not a feasible solution

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Lactobacillus reuteri strain GMNL-263 capable of improving hypertension and composition thereof
  • Lactobacillus reuteri strain GMNL-263 capable of improving hypertension and composition thereof
  • Lactobacillus reuteri strain GMNL-263 capable of improving hypertension and composition thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0049] Embodiment 1, the GMNL-263 that kills by heat has the effect of lowering blood pressure

[0050] This example is a human clinical trial. In view of the fact that patients with type II diabetes are prone to high blood pressure, the patients are mainly diagnosed with type II diabetes for more than 6 months. The other inclusion conditions are: 7%18.5; exclusion criteria: pregnancy / pregnancy; suffering from major diseases within 3 years, such as cancer (except for benign tumors with stable control), renal failure / dialysis, Heart disease, stroke, autoimmune disease, consumption of blood sugar-improving health care products other than hypoglycemic drugs four weeks before and during the test, regular consumption of probiotic products, regular use of antibiotics, abnormal liver and kidney function, unsound gastrointestinal tract, and those who cannot take drugs orally .

[0051] This example is registered on the clinical trial public website (Clinicaltrial.gov) with the accessi...

Embodiment 2

[0063] Example 2. Heat-killed GMNL-263 has the effect of lowering blood pressure by reducing the pro-inflammatory cytokine IL-1β

[0064] In order to test the mechanism through which GMNL-263 achieves the effect of lowering blood pressure, further analysis of the changes in the content of cytokines was carried out. First, collect the blood samples of the three groups of subjects at the beginning of the experiment (0M) and six months later (6M), and use the ELISA kit to analyze the content of various cytokines, including human IL-6 (Cat#900- K16, PeproTech, USA), human IL-10 (Cat#900-K21, PeproTech, USA), human TNF-α (Cat#50-114-2609, eBioscience, USA), human IL-1β (Cat#437005, Biolegend, USA), the data processing was six months (6M) minus the net change value of the beginning (0M), and further statistical analysis was performed with a two-sample t test.

[0065] The results showed that after taking GMNL-263 for six months, compared with the placebo group, the IL-1β in the blo...

Embodiment 3

[0068] Example 3. Heat-killed GMNL-263 has the effect of lowering blood pressure by enhancing the expression of intestinal Bifidobacteria

[0069] In order to clarify whether the antihypertensive effect of GMNL-263 is related to the regulation of intestinal probiotic flora, fecal samples were collected from the subjects at the beginning of the experiment (0M) and six months (6M) to quantify the polymerase chain reaction ( Quantitative polymerase chain reaction, Q-PCR) to analyze the DNA in the feces bacteria phase, and calculate the growth and decline changes of the bacteria phase after taking probiotics for six months. (Thresholdcycle) value-CT value of total bacteria)=△Ct, △Ct-(CT value obtained by Q-PCR of fecal DNA of those who have not yet taken it-CT value of total bacteria)=△△Ct; convert it to 2 -△△Ct , which is the growth and decline of the bacterial phase after taking probiotics for six months.

[0070] Using Q-PCR to analyze stool bacteria phase can be divided into ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a lactobacillus composition. The lactobacillus composition comprises lactobacillus reuteri GMNL-263, wherein the lactobacillus reuteri GMNL-263 is a heat-killing bacterium, a blood pressure lowering effect is achieved by inhibiting proinflammatory cytokine IL-1[beta] and enhancing the growth of a bifidobacterium, and the lactobacillus composition is a pharmaceutical composition, a nutritional supplement, health food or combination of the pharmaceutical composition, the nutritional supplement and the health food.

Description

technical field [0001] The invention relates to the field of microorganisms, in particular to the composition of Lactobacillus for improving high blood pressure. Background technique [0002] Blood pressure is the pressure exerted by the blood on the walls of blood vessels through the compression and pulsation of the heart. By maintaining blood pressure, it promotes blood circulation throughout the body, and then carries out nutrient transmission and waste metabolism; there are two types of blood pressure, systolic blood pressure and diastolic blood pressure, which are the systole or diastole when the heart beats Measurements; Normal blood pressure ranges from 90–139 mmHg systolic (highest reading) and 60–89 mmHg diastolic (lowest reading). [0003] Hypertension is a chronic disease caused by elevated arterial blood pressure, and it is also the most common chronic disease in China. When the blood pressure increases, the burden on the heart to push blood to circulate in the ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K35/747A61P9/12A23L33/135A23K10/16A23K10/18
CPCA61K35/747A61P9/12A23L33/135A23K10/16A23K10/18A23V2002/00A23V2400/173A23V2400/51A23V2200/326A23V2200/328
Inventor 陈奕兴蔡宛桦
Owner GENMONT BIOTECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com